Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

Tan, Antoinette R; Rubin, Eric H; Walton, Diana C; Shuster, Dale E; Wong, Y Nancy; Fang, Fang; Ashworth, Simon; Rosen, Lee S

Tan, Antoinette R; Rubin, Eric H; Walton, Diana C; Shuster, Dale E; Wong, Y Nancy; Fang, Fang; Ashworth, Simon; Rosen, Lee S.

Affiliation

Tan AR; The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA. tanan@umdnj.edu

Clin Cancer Res ; 15(12): 4213-9, 2009 Jun 15.

Article in En | MEDLINE | ID: mdl-19509146

Subject(s)

Furans/administration & dosage; Ketones/administration & dosage; Neoplasms/drug therapy; Tubulin Modulators/administration & dosage; Adult; Aged; Alopecia/chemically induced; Anorexia/chemically induced; Drug Administration Schedule; Fatigue/chemically induced; Female; Furans/adverse effects; Humans; Ketones/adverse effects; Male; Maximum Tolerated Dose; Middle Aged; Nausea/chemically induced; Neutropenia/etiology; Tubulin Modulators/adverse effects

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tubulin Modulators / Furans / Ketones / Neoplasms Type of study: Etiology_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2009 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google